世界最新医学信息文摘(连续型电子期刊)
世界最新醫學信息文摘(連續型電子期刊)
세계최신의학신식문적(련속형전자기간)
World Latest Medicine Information
2015年
49期
6-7
,共2页
肺肿瘤%恶性胸腔积液%非小细胞肺癌%重组人血管内皮抑制素%腔内化疗
肺腫瘤%噁性胸腔積液%非小細胞肺癌%重組人血管內皮抑製素%腔內化療
폐종류%악성흉강적액%비소세포폐암%중조인혈관내피억제소%강내화료
Lung tumor%Malignant pleural effusion%Non small cell lung cancer%Recombinant human endostatin%Intra cavity chemotherapy
目的:观察重组人血管内皮抑制素(商品名:恩度)联合博来霉素胸腔灌注化疗治疗非小细胞肺癌(NSCLC)合并恶性胸腔积液的疗效。方法对104例NSCLC合并恶性胸腔积液患者开放性非随机分为博来霉素45mg联合重组人血管内皮抑制素45mg(治疗组)和博来霉素45mg联合白介素Ⅱ100万 u(对照组),均在排尽胸腔积液后行胸腔序贯式灌注,1次/WK,连用6次观察疗效。结果治疗组总有效率为79.4%(54/68),显著高于对照组36.1%(13/36),P<0.01(χ2=19.256),其疾病控制率治疗组为97.1%(66/68),也显著优于对照组86.1%(31/36),P<0.05(χ2=4.427);生活质量KPS评分治疗组生活质量改善率为86.8%(59/68),显著高于对照组66.7%(24/36),P<0.05(χ2=6.338);两组均未见相关毒性反应,无治疗相关死亡病例发生。结论重组人血管内皮抑制素联合博来霉素腔内化疗治疗NSCLC合并恶性胸腔积液安全有效。
目的:觀察重組人血管內皮抑製素(商品名:恩度)聯閤博來黴素胸腔灌註化療治療非小細胞肺癌(NSCLC)閤併噁性胸腔積液的療效。方法對104例NSCLC閤併噁性胸腔積液患者開放性非隨機分為博來黴素45mg聯閤重組人血管內皮抑製素45mg(治療組)和博來黴素45mg聯閤白介素Ⅱ100萬 u(對照組),均在排儘胸腔積液後行胸腔序貫式灌註,1次/WK,連用6次觀察療效。結果治療組總有效率為79.4%(54/68),顯著高于對照組36.1%(13/36),P<0.01(χ2=19.256),其疾病控製率治療組為97.1%(66/68),也顯著優于對照組86.1%(31/36),P<0.05(χ2=4.427);生活質量KPS評分治療組生活質量改善率為86.8%(59/68),顯著高于對照組66.7%(24/36),P<0.05(χ2=6.338);兩組均未見相關毒性反應,無治療相關死亡病例髮生。結論重組人血管內皮抑製素聯閤博來黴素腔內化療治療NSCLC閤併噁性胸腔積液安全有效。
목적:관찰중조인혈관내피억제소(상품명:은도)연합박래매소흉강관주화료치료비소세포폐암(NSCLC)합병악성흉강적액적료효。방법대104례NSCLC합병악성흉강적액환자개방성비수궤분위박래매소45mg연합중조인혈관내피억제소45mg(치료조)화박래매소45mg연합백개소Ⅱ100만 u(대조조),균재배진흉강적액후행흉강서관식관주,1차/WK,련용6차관찰료효。결과치료조총유효솔위79.4%(54/68),현저고우대조조36.1%(13/36),P<0.01(χ2=19.256),기질병공제솔치료조위97.1%(66/68),야현저우우대조조86.1%(31/36),P<0.05(χ2=4.427);생활질량KPS평분치료조생활질량개선솔위86.8%(59/68),현저고우대조조66.7%(24/36),P<0.05(χ2=6.338);량조균미견상관독성반응,무치료상관사망병례발생。결론중조인혈관내피억제소연합박래매소강내화료치료NSCLC합병악성흉강적액안전유효。
Objective: To observe the effect of recombinant human endostatin (trade name: Endostar combined with bleomycin mycin pleural infusion chemotherapy in the treatment of non small cell lung cancer (NSCLC) for malignant pleural effusion of patients with.Methods: 104 cases of NSCLC with malignant pleural effusion were open non randomly divided into to Bo mycin 45mg combined with recombinant human vascular endostatin 45mg (treatment group) and Bo mycin 45mg combined with interleukin 2 100 million U (control group), were in drained pleural effusion underwent thoracic sequential perfusion, a /WK, QD for 6 times observe curative effect.Results: The total effective rate of treatment group was 36.1% (54/68), 97.1% (13/36),P<0.01 (χ2=19.256), and the control group was 86.1% (66/68), and 86.8% (χ2=4.427) P score was significantly higher than that of control group (KPS), 66.7% (59/68), 31/36 0.05 (24/36),P two (χ2=6.338).Conclusion: Recombinant human endostatin combined with the treatment of NSCLC combined with malignant pleural effusion is safe and effective in the treatment of malignant pleural effusion.